As of 2025-07-05, the Relative Valuation of Protagonist Therapeutics Inc (PTGX) is 18.22 USD. This relative valuation is based on P/E multiples. With the latest stock price at 51.05 USD, the upside of Protagonist Therapeutics Inc based on Relative Valuation is -64.3%.
The range of the Relative Valuation is 9.18 - 36.19 USD.
| Range | Selected | |
| Trailing P/E multiples | 21.5x - 39.9x | 27.0x |
| Forward P/E multiples | 25.1x - 47.7x | 32.7x |
| Fair Price | 9.18 - 36.19 | 18.22 |
| Upside | -82.0% - -29.1% | -64.3% |
| Date | P/E |
| 2025-07-03 | 56.31 |
| 2025-07-02 | 55.91 |
| 2025-07-01 | 55.38 |
| 2025-06-30 | 60.96 |
| 2025-06-27 | 61.43 |
| 2025-06-26 | 60.90 |
| 2025-06-25 | 60.05 |
| 2025-06-24 | 59.21 |
| 2025-06-23 | 58.86 |
| 2025-06-20 | 58.83 |
| 2025-06-18 | 59.47 |
| 2025-06-17 | 60.90 |
| 2025-06-16 | 60.29 |
| 2025-06-13 | 62.18 |
| 2025-06-12 | 62.12 |
| 2025-06-11 | 61.04 |
| 2025-06-10 | 62.18 |
| 2025-06-09 | 61.41 |
| 2025-06-06 | 59.98 |
| 2025-06-05 | 59.36 |
| 2025-06-04 | 56.84 |
| 2025-06-03 | 56.32 |
| 2025-06-02 | 55.31 |
| 2025-05-30 | 52.36 |
| 2025-05-29 | 52.48 |
| 2025-05-28 | 50.46 |
| 2025-05-27 | 51.21 |
| 2025-05-23 | 50.36 |
| 2025-05-22 | 50.64 |
| 2025-05-21 | 50.54 |
| 2025-05-20 | 51.41 |
| 2025-05-19 | 50.26 |
| 2025-05-16 | 49.07 |
| 2025-05-15 | 48.98 |
| 2025-05-14 | 48.28 |
| 2025-05-13 | 48.83 |
| 2025-05-12 | 49.93 |
| 2025-05-09 | 47.40 |
| 2025-05-08 | 48.44 |
| 2025-05-07 | 47.53 |
| 2025-05-06 | 46.34 |
| 2025-05-05 | 48.84 |
| 2025-05-02 | 50.20 |
| 2025-05-01 | 49.62 |
| 2025-04-30 | 50.54 |
| 2025-04-29 | 50.32 |
| 2025-04-28 | 48.96 |
| 2025-04-25 | 49.07 |
| 2025-04-24 | 49.47 |
| 2025-04-23 | 50.91 |